Malta - angleščina - Malta Medicines Authority

central procurement & supplies unit - phospholipids - endotracheopulmonary instillation, suspension - phospholipids 120 mg - other respiratory system products

Malta - angleščina - Malta Medicines Authority

chiesi farmaceutici s.p.a - phospholipids - endotracheopulmonary instillation, suspension - phospholipids 120 mg - other respiratory system products

Malta - angleščina - Malta Medicines Authority

chiesi farmaceutici s.p.a via palermo 26/a, 43122 parma, italy - phospholipids - endotracheopulmonary instillation, suspension - phospholipids 80 milligram(s)/millilitre - other respiratory system products

Malta - angleščina - Malta Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - phospholipids - endotracheopulmonary instillation, suspension - phospholipids 80 mg/ml - other respiratory system products

Združeni arabski emirati - angleščina - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

gulf drug llc dubai-street no 10 - phospholipids - injection - 45mg/ml - respiratory system-respiratory stimulants , surfactants

Malezija - angleščina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - phospholipids from soybeans -

Malezija - angleščina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

imeks pharma sdn. bhd. - phospholipids from soya beans -

Izrael - angleščina - Ministry of Health

abic marketing ltd, israel - phospholipids fraction from porcine lung - suspension - phospholipids fraction from porcine lung 80 mg/ml - lung surfactants - treatment of preterm babies with respiratory distress syndrome (rds). prophylactic use in premature infants at high risk of rds.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

abbvie limited - bovine lung lipids 25 mg/ml (total phospholipids); colfosceril palmitate 11 mg/ml - 15.5 mg/ml (disaturated phosphatidylcholine); palmitic acid 1.4 mg/ml - 3.5 mg/ml (free fatty acid); tripalmitin 0.5 mg/ml - 1.75 mg/ml (triglycerides) - intratracheal suspension - 25 mg/ml - active: bovine lung lipids 25 mg/ml (total phospholipids) colfosceril palmitate 11 mg/ml - 15.5 mg/ml (disaturated phosphatidylcholine) palmitic acid 1.4 mg/ml - 3.5 mg/ml (free fatty acid) tripalmitin 0.5 mg/ml - 1.75 mg/ml (triglycerides) excipient: sodium chloride water for injection - survanta is indicated for prevention and treatment ("rescue") of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants. survanta significantly reduces the incidence of rds, mortality due to rds and air leak complications.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

abbvie inc. - beractant (unii: s866o45pig) (beractant phospholipids - unii:lja7v5fcw8) - calfactant 25 mg in 1 ml - survanta is indicated for prevention and treatment (“rescue”) of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants. none